The risk of malignancy of atypical urothelial cells of undetermined significance in patients treated with chemohyperthermia or electromotive drug administration

Chemohyperthermia (C‐HT) or electromotive drug administration (EMDA) are alternative therapies to radical cystectomy in patients with non‐muscle‐invasive bladder cancer who do not respond to intravesical therapy with bacille Calmette‐Guérin.

[1]  L. Larocca,et al.  Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy). , 2017, Pathology, research and practice.

[2]  C. VandenBussche,et al.  Improved risk stratification for patients with high‐grade urothelial carcinoma following application of the Paris System for Reporting Urinary Cytology , 2017, Cancer cytopathology.

[3]  Shellaine R. Frazier,et al.  Accuracy and Reproducibility of Nuclear/Cytoplasmic Ratio Assessments in Urinary Cytology Specimens , 2017, Diagnostic cytopathology.

[4]  F. Brimo,et al.  Impact of Implementing the Paris System for Reporting Urine Cytology in the Performance of Urine Cytology:  A Correlative Study of 124 Cases. , 2016, American Journal of Clinical Pathology.

[5]  G. Fadda,et al.  Comparison between cytospin and liquid‐based cytology in urine specimens classified according to the Paris System for Reporting Urinary Cytology , 2016, Cancer cytopathology.

[6]  D. Rosenthal,et al.  The Paris system for reporting urinary cytology , 2016 .

[7]  F. Mege-Lechevallier,et al.  Diagnostic terminology for urinary cytology reports including the new subcategories ‘atypical urothelial cells of undetermined significance’ (AUC‐US) and ‘cannot exclude high grade’ (AUC‐H) , 2014, Cytopathology : official journal of the British Society for Clinical Cytology.

[8]  G. Barkan,et al.  Evaluation of atypical urine cytology progression to malignancy , 2013, Cancer cytopathology.

[9]  C. VandenBussche,et al.  The Johns Hopkins Hospital template for urologic cytology samples , 2013, Cancer cytopathology.

[10]  M. Babjuk,et al.  [EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update]. , 2012, Actas urologicas espanolas.

[11]  Ofer Nativ,et al.  The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. , 2011, European urology.

[12]  Ghadeer A. Mokhtar,et al.  Diagnostic significance of atypical category in the voided urine samples: A retrospective study in a tertiary care center , 2010, Urology annals.

[13]  F. Brimo,et al.  Accuracy of urine cytology and the significance of an atypical category. , 2009, American journal of clinical pathology.

[14]  E. Rossi,et al.  Application of liquid-based preparation to non-gynaecologic exfoliative cytology. , 2008, Pathologica.

[15]  G. Venkataraman,et al.  Diagnostic significance of ‘atypia’ in instrumented versus voided urine specimens , 2008, Cancer.

[16]  T. Cenci,et al.  Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma. , 2008, American journal of clinical pathology.

[17]  P. Schellhammer,et al.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. , 2007, The Journal of urology.

[18]  P. Dey,et al.  Malignant atypical cell in urine cytology: a diagnostic dilemma , 2006, CytoJournal.

[19]  M. Chancellor,et al.  New frontiers in intravesical therapies and drug delivery. , 2006, European urology.

[20]  M. Valenti,et al.  Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. , 2006, The Lancet. Oncology.

[21]  V. Deshpande,et al.  Analysis of atypical urine cytology in a tertiary care center , 2005, Cancer.

[22]  P. Malmström,et al.  Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. , 2003, European urology.